ClearBridge Small Cap Strategy adds KWR, RNA, exits SEAT, GDRX among Q3 moves
Source: SeekingAlpha
2025-10-15 12:18:25 ET
More on LXP Industrial Trust, Wabash National, etc.
- Freshpet: Still Barking At A Potential Bargain
- GoodRx: Novo Deal And TrumpRx Talks Point To Ebitda/FCF Upside
- CG Oncology: Upgraded, Rising, But Should We Still Be Optimistic?
- GoodRx launches subscription program for men's hair loss
- ClearBridge SMID Cap Growth Strategy adds CRDO, RKLB, exits OSCR, RARE
Read the full article on Seeking Alpha
For further details see:
ClearBridge Small Cap Strategy adds KWR, RNA, exits SEAT, GDRX among Q3 moves
Ultragenyx Pharmaceutical Inc.
NASDAQ: RARE
RARE Trading
-5.17% G/L:
$21.81 Last:
672,373 Volume:
$22.78 Open:
RARE Latest News
February 23, 2026 08:30:00 am
Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
February 12, 2026 04:01:00 pm
Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
RARE Stock Data
$2,352,123,132
91,171,303
0.09%
84
N/A
Biotechnology & Life Sciences
Healthcare
US
Novato
